Abstract 274P
Background
B-cell lymphoma is associated with an aggressive clinical course, is prone to rapid growth and early progression. Studying gene expression profiles to identify molecular subgroups of lymphomas is a topical issue of haematology as it allows a personalized approach to treatment with high-dose polychemotherapy (PCT) regime with a monoclonal antibody. Such approach improves the immediate treatment efficacy and event-free survival rate. Purpose of the study was to increase the efficacy of therapy in patients with non-Hodgkin large B-cell lymphoma based on the examination of molecular genetic features of the tumor and the use of polychemotherapy based on mutational gene expression profile.
Methods
In this single-center prospective study, 44 patients with non-Hodgkin large B-cell lymphomas stages II-IV A & B were treated at the Department of Hemoblastosis at Kazakh Institute of Oncology and Radiology. Patients with mutated c-MYC gene were treated by high-dose PCT with R+HyperCVAD and we have analysed the treatment outcome.
Results
The FISH test revealed a mutation of c-MYC gene in non-Hodgkin large B-cell lymphoma patients. Therefore, these cases were classified as highly malignant and required high-dose PCT with a monoclonal antibody Rituximab followed by stem cell autotransplantation. This regime of PCT has improved the immediate efficacy of treatment. The patients (18 men and 26 women) were aged 27 to 58 years, with an average age of 42 years. B-cell lymphoma was confirmed in all cases; the complete response amounted to 80.0%; the disease-free survival (DFS) was 18 months (95% CI, 6.592-25.762, P = 0.003).
Conclusions
High-dose PCT in the R+HyperCVAD regimen (3-4 courses) followed by immunotherapy and autotransplantation of hemopoietic stem cells in patients with non-Hodgkin B-cell lymphoma have improved the immediate efficacy and long-term results of treatment of B-cell non-Hodgkin lymphoma.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Kazakh Institute of Oncology and Radiology.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
27P - The prognostic value of neutrophil to lymphocyte ratio (NLR) and 18F-FDG PET SUV in breast cancer patients underwent neoadjuvant chemotherapy
Presenter: Soong June Bae
Session: Poster display session
Resources:
Abstract
28P - Accuracy of core biopsy in predicting pathologic complete response in the breast in patients with complete/near complete clinical and radiological response (Complete Responders in the Breast – CRBr): A feasibility study
Presenter: Nisha Hariharan
Session: Poster display session
Resources:
Abstract
29P - Tumour response to neoadjuvant chemotherapy in breast cancer: Routine pathologic markers improve the predictive power of a cell-loss metric based on release of thymidine kinase 1 into blood
Presenter: Bernhard Tribukait
Session: Poster display session
Resources:
Abstract
30P - Comparison of metabolic changes between neoadjuvant chemotherapy and neoadjuvant endocrine therapy in premenopausal women with ER positive, HER2 negative breast cancer
Presenter: Ho-hyun Ryu
Session: Poster display session
Resources:
Abstract
31P - Circulating miR-155 as a potential therapeutic monitoring marker in breast cancer
Presenter: Sumadi Lukman Anwar
Session: Poster display session
Resources:
Abstract
32P - Profile of breast cancer epidemiology in Sanglah General Hospital, Denpasar, Bali from 2012 to 2019
Presenter: Citra Aryanti
Session: Poster display session
Resources:
Abstract
33P - Contrast enhanced chest CT in patients with breast cancer: Comprehensive imaging analysis and correlation with biological markers
Presenter: Bo Hwa Choi
Session: Poster display session
Resources:
Abstract
34P - Verification of metabolic regulatory mechanisms in androgen receptor-positive triple negative breast cancer
Presenter: Yuka Asano
Session: Poster display session
Resources:
Abstract
35TiP - Ribociclib plus goserelin with hormonal therapy versus physician choice chemotherapy in pre-/perimenopausal patients with HR+, HER2– inoperable locally advanced breast cancer (ABC): RIGHT choice study
Presenter: Yen-Shen Lu
Session: Poster display session
Resources:
Abstract
36TiP - A prospective study to assess response to neoadjuvant hormonal therapy in postmenopausal women with hormone-receptor positive breast cancer at a regional cancer centre in South India
Presenter: Shina Goyal
Session: Poster display session
Resources:
Abstract